Beta Bionics, Inc./$BBNX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Beta Bionics, Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Ticker
$BBNX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
353
ISIN
US08659B1026
Website
BBNX Metrics
BasicAdvanced
$586M
-
-$5.66
-
-
Price and volume
Market cap
$586M
52-week high
$21.62
52-week low
$8.89
Average daily volume
566K
Financial strength
Current ratio
15.881
Quick ratio
14.585
Long term debt to equity
1.737
Total debt to equity
2.223
Profitability
EBITDA (TTM)
-53.273
Gross margin (TTM)
53.93%
Net profit margin (TTM)
-101.62%
Operating margin (TTM)
-77.96%
Revenue per employee (TTM)
$200,000
Management effectiveness
Valuation
Price to revenue (TTM)
2.428
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
-2.853
Free cash flow yield (TTM)
-35.06%
Free cash flow per share (TTM)
-473.96%
Growth
Bulls say / Bears say
Beta Bionics reported a 36% increase in net sales to $17.6 million in Q1 2025, indicating strong market demand for its products. (investors.betabionics.com)
The company's installed customer base grew by 291% to 19,151 users in Q1 2025, reflecting successful adoption of its iLet Bionic Pancreas. (investors.betabionics.com)
Analysts at Leerink Partners initiated coverage with an 'outperform' rating and a $28.00 price target, suggesting confidence in the company's growth prospects. (etfdailynews.com)
Despite revenue growth, Beta Bionics reported a net loss of $28.7 million in Q1 2025, raising concerns about profitability. (investors.betabionics.com)
The company's gross margin declined by 482 basis points to 50.9% in Q1 2025, indicating potential challenges in cost management. (investors.betabionics.com)
Beta Bionics' stock reached a new 52-week low after missing earnings expectations, suggesting investor concerns about financial performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BBNX News
AllArticlesVideos
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
GlobeNewsWire·2 days ago
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor
GlobeNewsWire·2 weeks ago
Beta Bionics to Host Investor Event on June 22, 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beta Bionics, Inc. stock?
Beta Bionics, Inc. (BBNX) has a market cap of $586M as of July 04, 2025.
What is the P/E ratio for Beta Bionics, Inc. stock?
The price to earnings (P/E) ratio for Beta Bionics, Inc. (BBNX) stock is 0 as of July 04, 2025.
Does Beta Bionics, Inc. stock pay dividends?
No, Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Beta Bionics, Inc. dividend payment date?
Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Beta Bionics, Inc.?
Beta Bionics, Inc. (BBNX) does not currently have a Beta indicator.